Lv41
470 积分 2023-10-17 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3小时前
待确认
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
2个月前
已完结
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
2个月前
已完结
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
2个月前
已完结
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
3个月前
已完结
The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death
3个月前
已完结
Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma
5个月前
已完结
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
5个月前
已完结
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression
5个月前
已完结
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
7个月前
已完结
皖公网安备34019202002308
